司美格鲁肽作为成人隐匿性自身免疫糖尿病附加治疗的研究
本研究回顾性分析80例接受司美格鲁肽(口服或皮下)作为胰岛素附加治疗的成人隐匿性自身免疫糖尿病(LADA)患者。68例持续治疗至少6个月,结果显示糖化血红蛋白、体重指数和胰岛素每日总剂量显著降低,C肽水平和葡萄糖目标范围内时间增加,且β细胞功能保留者获益更明显。
要点
- 司美格鲁肽附加治疗可改善LADA患者的血糖代谢控制。
- β细胞功能保留的LADA患者从司美格鲁肽治疗中获益更大。
- 部分患者治疗后可停用胰岛素餐时大剂量。
核心结论
- 司美格鲁肽作为胰岛素附加治疗对LADA患者的糖代谢控制产生相关临床有益效应。
- 这些效应在β细胞功能保留的患者中更为明显。
研究设计与样本
- 回顾性研究,收集并分析80例接受司美格鲁肽(口服或皮下)作为胰岛素附加治疗的LADA患者数据。
主要发现
- 80例中68例持续司美格鲁肽治疗至少6个月(口服57/68,皮下11/68),12/80例停药。
- 治疗6个月后,司美格鲁肽使用者糖化血红蛋白、体重指数和胰岛素每日总剂量均显著降低。
- 血清C肽水平和葡萄糖目标范围内时间增加,低于目标范围时间无变化。
- β细胞功能残留者体重指数和胰岛素每日总剂量降低幅度更大。
- β细胞质量保留亚组相比C肽产生差者目标范围内时间改善更明显。
临床怎么用
- 可考虑将司美格鲁肽作为LADA患者胰岛素的附加治疗以改善血糖代谢控制。
- β细胞功能保留的LADA患者可能从司美格鲁肽治疗中获益更多。
局限性
- 回顾性研究设计。
- 样本量有限(80例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Semaglutide, a GLP-1R agonist (GLP-1RA), has demonstrated high efficacy in the management of type 2 diabetes. Few data in literature are available regarding the use of this agent in patients affected by latent autoimmune diabetes in adults (LADA). The purpose of this study is to analyze the efficacy of semaglutide use in patients affected by LADA. MATERIALS AND METHODS: In this retrospective study, we collected and analyzed data of 80 patients with LADA treated with semaglutide, either oral or subcutaneous, as an add-on therapy to insulin. Laboratory and clinical parameters and metrics from continuous glucose monitoring were collected where available. RESULTS: Among 80 patients, 68 continued semaglutide (57/68 oral and 11/68 subcutaneous) for at least 6 months, whereas 12/80 patients discontinued treatment. After 6 months, semaglutide users showed statistically significant reduction in glycated hemoglobin, body mass index, and insulin total daily dose. Interestingly, serum C-peptide levels and the time-in-range values increased, without changes in the time below range. Subjects with residual β-cell function showed a higher body mass index and insulin total daily dose reduction. Moreover, the subgroup of subjects with preserved β-cell mass showed a greater improvement in time in range as compared to those with poor C-peptide production. Finally, 14/68 subjects suspended insulin bolus administration after starting semaglutide. CONCLUSION: Semaglutide as an add-on treatment to insulin exerted relevant clinical beneficial effects on the glycometabolic control in patients with LADA. These effects are enhanced in those patients with preserved β-cell function.
引用
- Lunati ME, Cimino V, Bernasconi D, et al. The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults. J Clin Endocrinol Metab. 2026. PMID: 41729594. doi:10.1210/clinem/dgag072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。